5,368 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Smithbridge Asset Management Inc. DE

Smithbridge Asset Management Inc. DE purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 5,368 shares of the biopharmaceutical company’s stock, valued at approximately $3,405,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $25,000. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 15 shares during the period. Tompkins Financial Corp acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $32,000. Finally, Curat Global LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $521.84 on Friday. The firm has a 50-day moving average of $563.74 and a 200-day moving average of $651.53. The company has a market cap of $56.34 billion, a P/E ratio of 13.63, a P/E/G ratio of 2.34 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. During the same quarter in the prior year, the company earned $9.55 EPS. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

Analysts Set New Price Targets

Several brokerages have issued reports on REGN. UBS Group decreased their price target on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating for the company in a research report on Thursday, June 5th. Robert W. Baird reduced their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research note on Friday, April 25th. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. Royal Bank of Canada lowered shares of Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price objective on the stock. in a research note on Friday, May 30th. Finally, Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.